[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:richter-syndrome":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":103,"states":104},"Richter Syndrome",15,13,[8,16,22,29,35,41,47,53,59,65,72,77,83,89,96],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04679012","Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation",[12],"Phase 2","RECRUITING","2026-08-26T02:19:31.671303Z","2026-05-05T02:43:27.838740Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05536349","Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)",[12],"2026-08-26T02:16:04.914942Z","2026-05-05T02:43:27.292018Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06735664","Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation",[26],"Phase 1","2026-08-26T02:17:16.126291Z","2026-05-05T02:43:27.288261Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06043674","Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation",[12],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:26.951864Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06863402","Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype",[12],"2026-08-26T02:15:54.846520Z","2026-07-24T01:27:14.890802Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05873712","Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome",[12],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:27.245708Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT05388006","Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[12],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:27.040607Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[12],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT07451054","CD45BE-HSPC + CART-45 Cells",[26],"2026-08-26T02:16:39.977107Z","2026-05-13T02:55:06.706937Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":70,"content_modified":71},"NCT04491370","Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma",[69],"Phase 1\u002FPhase 2","2026-08-26T02:17:50.500039Z","2026-05-05T02:43:28.622855Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":51,"content_modified":76},"NCT06191887","B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies",[26],"2026-05-05T02:43:28.173828Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT04728893","Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)",[12],"2026-08-26T02:17:42.501124Z","2026-05-05T02:43:28.133797Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":87,"content_modified":88},"NCT04771572","Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS\u002FMPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.",[26],"2026-08-26T02:18:06.247899Z","2026-05-05T02:43:27.598768Z",{"nct_id":90,"title":91,"phases":92,"status":93,"updated_at":94,"content_modified":95},"NCT07168486","CD19.20.22 CAR T-cells for Patients With Relapsed\u002FRefractory B-Cell Lymphomas",[26],"ENROLLING_BY_INVITATION","2026-08-26T02:19:19.975067Z","2026-06-16T05:54:07.870155Z",{"nct_id":97,"title":98,"phases":99,"status":100,"updated_at":101,"content_modified":102},"NCT05672173","Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:36:55.348098Z","2026-05-05T02:43:29.389953Z",[],[105,109,113,116,120,124,127],{"state":106,"count":107,"slug":108},"New York",6,"new-york",{"state":110,"count":111,"slug":112},"California",5,"california",{"state":114,"count":111,"slug":115},"Ohio","ohio",{"state":117,"count":118,"slug":119},"Texas",4,"texas",{"state":121,"count":122,"slug":123},"Massachusetts",3,"massachusetts",{"state":125,"count":122,"slug":126},"Minnesota","minnesota",{"state":128,"count":122,"slug":129},"North Carolina","north-carolina"]